Full Breakdown
Trump’s Executive Order: A Turning Point for the Hemp Industry
12/27/2025, 4:30:04 AM
Executive Order Reshapes Hemp Regulations
President Donald Trump has issued an executive order aimed at expediting the reclassification of marijuana under federal law, a move that could significantly impact the hemp industry. The order directs the Justice Department to shift marijuana from Schedule I to Schedule III of the Controlled Substances Act, which would categorize it alongside substances deemed to have moderate medical value. This change is seen as a potential boon for hemp growers and businesses, particularly in states like North Carolina, where medicinal cannabis remains illegal. Natacha Andrews, president of the National Association of Black Cannabis Lawyers, noted that this reclassification could benefit populations in need of medical cannabis.
Industry Response and Legislative Implications
The hemp industry has been under pressure since a provision in a government funding bill was passed in November, which threatens to ban many hemp-derived products, including full-spectrum CBD. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, described Trump's order as a "lifeline" that strengthens the industry's position as Congress considers restrictions. The provision allows a one-year period before the ban takes effect, prompting industry leaders to lobby for an extension of this timeline. Thomas Winstanley, executive vice president at Edibles.com, emphasized the need for concurrent regulation of cannabis and hemp, highlighting the intrinsic relationship between the two.
Criticism and Concerns
Despite the optimism surrounding the executive order, some stakeholders caution that it does not alter existing laws. Chris Lindsey, vice president for state policy and advocacy at the American Trade Association for Cannabis and Hemp, pointed out that the order primarily supports true CBD companies while leaving those marketing synthetic THC products unaddressed. Additionally, while the reclassification facilitates medical research, it does not legalize medical use unless the Food and Drug Administration approves specific cannabis-based products.
Broader Context and Historical Significance
Historically, marijuana has been classified as a Schedule I substance since 1970, despite arguments from figures like Francis Young, a former DEA chief administrative law judge, who asserted that marijuana does not belong in this category. The recent review by the Department of Health and Human Services (HHS) found credible scientific support for marijuana's medical applications, leading to the current reclassification effort. However, Trump clarified that his order does not legalize marijuana, a point that has drawn criticism given the ongoing conflict between state legalization and federal prohibition.
What's Next for the Hemp Industry?
As the hemp industry navigates this regulatory landscape, stakeholders remain hopeful that the executive order will lead to better product standards and increased research opportunities. The next steps involve legislative discussions and potential updates to how hemp-derived products are defined and regulated. The coming months will be crucial as industry leaders advocate for favorable outcomes in light of the looming restrictions set to take effect next year.
Verbatim Quotes
- “In terms of where thepolitical discussionis going to go, it is definitely a lifeline, and definitely gives us a whole lot more leverage to ensure that what Congress does in the next 11 months is going to be favorable for the industry,” — Jonathan Miller, General Counsel, U.S. Hemp Roundtable
- “For the most part, it is viewed as a win in some regard, because it is a move forward,” — Natacha Andrews, President, National Association of Black Cannabis Lawyers
- “What this does, I think more broadly, is it creates a more earnest conversation with Congress, knowing that the executive branch is now signaling that cannabinoid-based products may have health efficacy,” — Thomas Winstanley, Executive Vice President, Edibles.com
